Chapter 17

Diagnosis, Therapy and Prevention of Wernicke's Encephalopathy

R. Galvin

R. Galvin

Cork University Hospital, Wilton, Cork, Ireland

Search for more papers by this author
G. Brathen

G. Brathen

Trondheim University Hospital, Trondheim, Norway

Search for more papers by this author
A. Ivashynka

A. Ivashynka

National Neurology and Neurosurgery Research Centre, Minsk, Belarus

Search for more papers by this author
M. Hillbom

M. Hillbom

Oulu University Hospital, Oulu, Finland

Search for more papers by this author
R. Tanasescu

R. Tanasescu

Colentina Hospital, University of Medicine and Pharmacy, Carol Davila, Bucharest, Romania

Search for more papers by this author
M. A. Leone

M. A. Leone

Azienda Ospedaliero-Universitaria Maggiore della Carita, Novara, Italy

Search for more papers by this author
First published: 21 September 2011

Summary

Backround: Although Wernicke encephalopathy (WE) is a preventable and treatable disease it often remains undiagnosed.

Objectives: To create practical guidelines for diagnosis, management and prevention of the disease.

Methods: we searched Medline, EMBASE, LILACS and the Cochrane Library.

Recommendations: (1) The clinical diagnosis of WE should take into account the different presentations of clinical signs between alcoholics and non-alcoholics (Level C); although prevalence is higher in alcoholics, WE should be suspected in all clinical conditions which could lead to thiamine deficiency (good practice point). (2) The clinical diagnosis of WE in alcoholics requires two of the following four signs: (a) dietary deficiencies, (b) eye signs, (c) cerebellar dysfunction, and (d) either an altered mental state or mild memory impairment (Level B). (3) Total thiamine in a blood sample should be measured immediately before its administration (good practice point). (4) MRI should be used to support the diagnosis of acute WE in alcoholics and non-alcoholics (Level B). (5) Thiamine is indicated for the treatment of suspected or manifest WE. It should be given, before any carbohydrate, 200 mg three times daily, preferably intravenously (Level C). (6) The overall safety of thiamine is very good (Level B). (7) After bariatric surgery we recommend follow-up of thiamine status for at least 6 months (Level B) and parenteral thiamine supplementation (good practice point). (8) Parenteral thiamine should be given to all at-risk subjects admitted to the Emergency Room (good practice point). (9) Patients dying from symptoms suggesting WE should have an autopsy (good practice point).

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.